NCT01934894 - Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

April 30, 2017

Conditions

Metastatic Breast Cancer With Intracranial Metastases

Interventions

DRUG

cabazitaxel

DRUG

lapatinib

Trial Locations (4)

Florida Cancer Specialists-North, St. Petersburg

Florida Cancer Specialists - South, Fort Myers

Tennessee Oncology, Nashville

Oncology Hematology Care Inc., Cincinnati